Quick Answer
Grace Therapeutics, Inc. reported Research And Development Expense of $9.51 million for the year ending 2025.
- Grace Therapeutics, Inc. showed an increase of +103.1% in Research And Development Expense from 2024 to 2025.
- This data is from Grace Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on June 23, 2025.
- XBRL data for this metric is available from 2016 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2019: $6.19 million | Q3 2019: $3.95 million | Q4 2019: $3.91 million | Q2 2020: $1.76 million | Q3 2020: $1.29 million | Q4 2020: $678.0 thousand | Q2 2021: $469.0 thousand | Q3 2021: $585.0 thousand | Q4 2021: $2.18 million | Q2 2022: $2.59 million | Q3 2022: $3.29 million | Q4 2022: $2.45 million | Q2 2023: $1.10 million | Q3 2023: $460.0 thousand | Q4 2023: $1.44 million | Q2 2024: $2.71 million | Q3 2024: $2.98 million | Q4 2024: $2.19 million | Q2 2025: $955.0 thousand | Q3 2025: $568.0 thousand | Q4 2025: $462.0 thousand.
- Over the full 12 years of available data (2016 to 2025), Grace Therapeutics, Inc.'s Research And Development Expense has grown by 25.7%.
- Historical annual values: Fiscal year 2025: $9.51 million | Fiscal year 2024: $4.68 million | Fiscal year 2023: $9.97 million | Fiscal year 2022: $5.56 million | Fiscal year 2021: $4.17 million | Fiscal year 2020: $15.97 million | Fiscal year 2019: $29.37 million | Fiscal year 2018: $15.67 million | Fiscal year 2017: $426.0 thousand | Fiscal year 2017: $7.65 million | Fiscal year 2017: $7.23 million | Fiscal year 2016: $7.57 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: